Travere Therapeutics
Rare disease biopharmaceutical company focused on kidney and metabolic conditions, headquartered in San Diego, California.
Travere Therapeutics Official WebsiteTravere Therapeutics is a publicly traded biopharmaceutical company (Nasdaq: TVTX) headquartered in San Diego, California. Founded in 2008 as Retrophin and rebranded in 2020, the company focuses on identifying, developing, and delivering therapies for rare kidney and metabolic diseases, including IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS), and Classical Homocystinuria. The company employs approximately 497 people.
Travere's lead product, FILSPARI® (sparsentan), received full FDA approval in September 2024 for slowing kidney function decline in adults with primary IgAN, supported by Phase 3 PROTECT study data. The European Commission also granted conditional marketing authorization for FILSPARI in April 2024 in partnership with CSL Vifor. A supplemental NDA for FILSPARI in FSGS is under FDA review with a PDUFA target date of January 13, 2026, which if approved would mark the first FDA-approved treatment for that condition.
Travere has seen substantial revenue growth, with total revenue reaching approximately $490.7 million in FY2025, up from $233.2 million in FY2024, driven primarily by FILSPARI net product sales. Innovations in rare kidney disease treatment, orphan drug development, and regulatory pathways for rare conditions are directly relevant to the company's commercial and pipeline strategy.